‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-01-05 DOI:10.1038/s41571-023-00857-9

Garth W. Strohbehn, Bishal Gyawali

引用次数: 0

Abstract

The FDA approval of perioperative pembrolizumab, an approach that combines neoadjuvant and adjuvant therapy with this agent, for patients with early stage non-small-cell lung cancer (NSCLC) contradicts its own stated standard for combination therapies. Given the large population of patients with early stage NSCLC and the high costs of pembrolizumab, whether the adjuvant component provides incremental benefit is an important question.

查看原文本刊更多论文

组成部分的贡献 "和围手术期免疫检查点抑制剂的先例

美国食品药品管理局（FDA）批准对早期非小细胞肺癌（NSCLC）患者使用围手术期的 pembrolizumab（一种结合了新辅助治疗和辅助治疗的药物），这与该局自己规定的联合疗法标准相矛盾。鉴于早期 NSCLC 患者人数众多，而 pembrolizumab 的成本高昂，因此辅助治疗是否能带来增量获益是一个重要问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.